AAAAAA
Results:
1-14
|
Results: 14
Authors:
PETTIGREW LC
BIEBER F
LETTIERI J
WERMELING DP
FREDERICK D
SCHMITT A
TIKHTMAN AJ
ASHFORD JW
SMITH CD
WEKSTEIN DR
MARKESBERY WR
ORAZEM J
RUZICKA BB
MAS J
GULANSKI B
Citation: Lc. Pettigrew et al., PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF METRIFONATE IN PATIENTS WITH ALZHEIMERS-DISEASE, Journal of clinical pharmacology, 38(3), 1998, pp. 236-245
Authors:
CUMMINGS JL
CYRUS PA
BIEBER F
MAS J
ORAZEM J
GULANSKI B
Citation: Jl. Cummings et al., METRIFONATE TREATMENT OF THE COGNITIVE DEFICITS OF ALZHEIMERS-DISEASE, Neurology, 50(5), 1998, pp. 1214-1221
Authors:
MORRIS JC
CYRUS PA
ORAZEM J
MAS J
BIEBER F
RUZICKA BB
GULANSKI B
Citation: Jc. Morris et al., METRIFONATE BENEFITS COGNITIVE, BEHAVIORAL, AND GLOBAL FUNCTION IN PATIENTS WITH ALZHEIMERS-DISEASE, Neurology, 50(5), 1998, pp. 1222-1230
Authors:
CUTLER NR
JHEE SS
CYRUS P
BIEBER F
TANPIENGCO P
SRAMEK JJ
GULANSKI B
Citation: Nr. Cutler et al., SAFETY AND TOLERABILITY OF METRIFONATE IN PATIENTS WITH ALZHEIMERS-DISEASE - RESULTS OF A MAXIMUM TOLERATED DOSE STUDY, Life sciences, 62(16), 1998, pp. 1433-1441
Authors:
CUTLER NR
CYRUS P
SRAMEK JJ
BIEBER F
TANPIENGCO P
GULANSKI B
Citation: Nr. Cutler et al., THE MAXIMUM TOLERATED DOSE (MTD) OF METRIFONATE IN ALZHEIMERS PATIENTS, Biological psychiatry, 43, 1998, pp. 156-156
Authors:
DORAISWAMY PM
BIEBER F
KAISER L
GULANSKI B
Citation: Pm. Doraiswamy et al., THE ALZHEIMERS-DISEASE ASSESSMENT SCALE .6. NONCOGNITIVE SIGNS AND SYMPTOMS IN OUTPATIENTS WITH ALZHEIMERS-DISEASE, Psychopharmacology bulletin, 33(3), 1997, pp. 514-514
MEMORY, LANGUAGE, AND PRAXIS IN ALZHEIMERS-DISEASE - NORMS FOR OUTPATIENT CLINICAL-TRIAL POPULATIONS
Authors:
DORAISWAMY PM
BIEBER F
KAISER L
CONNORS K
KRISHNAN KR
REUNINGSCHERER J
GULANSKI B
Citation: Pm. Doraiswamy et al., MEMORY, LANGUAGE, AND PRAXIS IN ALZHEIMERS-DISEASE - NORMS FOR OUTPATIENT CLINICAL-TRIAL POPULATIONS, Psychopharmacology bulletin, 33(1), 1997, pp. 123-128
Authors:
MORRIS J
CYRUS P
ORAZEM J
MAS J
BIEBER F
GULANSKI B
Citation: J. Morris et al., METRIFONATE - POTENTIAL THERAPY FOR ALZHEIMERS-DISEASE, Neurology, 48(6), 1997, pp. 8-8
Authors:
DORAISWAMY PM
BIEBER F
KAISER L
KRISHNAN KR
REUNINGSCHERER J
GULANSKI B
Citation: Pm. Doraiswamy et al., THE ALZHEIMERS-DISEASE ASSESSMENT SCALE - PATTERNS AND PREDICTORS OF BASE-LINE COGNITIVE PERFORMANCE IN MULTICENTER ALZHEIMERS-DISEASE TRIALS, Neurology, 48(6), 1997, pp. 1511-1517
Authors:
CYRUS P
ORAZEM J
RUZICKA B
MAS J
BIEBER F
GULANSKI B
Citation: P. Cyrus et al., METRIFONATE TREATMENT OF ALZHEIMERS-DISEASE (AD) - INFLUENCE OF DEMOGRAPHIC CHARACTERISTICS, Journal of the American Geriatrics Society, 45(9), 1997, pp. 40-40
Authors:
MORICH FJ
BIEBER F
LEWIS JM
KAISER L
CUTLER NR
ESCOBAR JI
WILLMER J
PETERSEN RC
REISBERG B
AUERBACH S
BAUMEL B
BOYER J
BRANCONNIER R
BURNS E
CUTLER N
DUBOVSKY S
EARL N
EISNER L
ESCOBAR J
FANALE J
FERGUSON J
FORNAZZARI L
FOX J
FREY J
FUHR J
GOCKE J
GROSS J
HARTFORD J
HIRSCH C
HOLLANDER J
ITIL T
JAGUST W
JANN M
KREMENITZER M
LANDBLOOM R
LUCAS P
LICHTMAN H
MATTES J
MEYER J
PARHAD I
PETERSEN R
SABIN T
SHELTON P
SIEGAL A
SMITH W
THEIN S
TUPPER J
WALSHE T
Citation: Fj. Morich et al., NIMODIPINE IN THE TREATMENT OF PROBABLE ALZHEIMERS-DISEASE - RESULTS OF 2 MULTICENTER TRIALS, Clinical drug investigation, 11(4), 1996, pp. 185-195
Authors:
DORAISWAMY PM
BIEBER F
REUNINGSCHERER J
KRISHNAN KR
KAISER L
GULENSKI B
Citation: Pm. Doraiswamy et al., THE ALZHEIMERS-DISEASE ASSESSMENT SCALE - PREDICTORS OF BASE-LINE COGNITIVE PERFORMANCE IN CLINICAL-TRIALS, Psychopharmacology bulletin, 32(3), 1996, pp. 434-434
Authors:
SPAETHE R
DUMOULIN A
BIEBER F
BOHM W
Citation: R. Spaethe et al., PRINCIPLES OF IMMUNAPHERESIS AND SPECIFIC ELIMINATION OF PLASMA COMPONENTS, Biomaterials, artificial cells, and immobilization biotechnology, 21(2), 1993, pp. 239-251
Authors:
DUMOULIN A
MULLERDERLICH J
BIEBER F
RICHTER WO
FREI U
MULLER R
SPAETHE R
Citation: A. Dumoulin et al., ANTIBODY-BASED IMMUNOADSORPTION AS A THERAPEUTIC MEANS, Blood purification, 11(3), 1993, pp. 145-149
Risultati:
1-14
|